Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

Ruben A Mesa, Jean Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason R Gotlib, Heinz Gisslinger, Richard S Levy, Andres Siulnik, Vikas Gupta, Mahmudul Khan, John F DiPersio, Mari McQuitty, John Catalano, Deborah S Hunter, Laurent Knoops, Michael Werner Nikolaus Deininger, Francisco Cervantes, Carole B Miller, Alessandro M Vannucchi, Richard T SilverTiziano Barbui, Moshe Talpaz, Giovanni Barosi, Elliott F Winton, Estella Mendeson, Jimmie H Harvey, Murat O Arcasoy, Elizabeth Olson Hexner, Roger M Lyons, Ronald L Paquette, Azra Raza, William Sun, Victor A Sandor, Hagop M Kantarjian, Claire N Harrison

    Research output: Contribution to journalArticleResearchpeer-review

    31 Citations (Scopus)

    Abstract

    Prior to Janus kinase inhibitors, available therapies for myelofibrosis were generally supportive and did not improve survival. This analysis compares efficacy outcomes of patients with myelofibrosis in the control arms (placebo [n=154] and best available therapy [n=73]) from the two phase 3 COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment (COMFORT) studies. Spleen volume was assessed by magnetic resonance imaging/ computed tomography at baseline and every 12 weeks through week 72; spleen length was assessed by palpation at each study visit. Health-related quality of life and symptoms were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items at baseline and in weeks 4, 8, 12, 16 and 24 in COMFORT-I and in weeks 8, 16, 24 and 48 in COMFORT-II. The demographic and baseline characteristics were similar between the control arms of the two studies. One patient who received placebo and no patients who received best available therapy had a ≥35% reduction in spleen volume from baseline at week 24. At 24 weeks, neither placebo nor best available therapy had produced clinically meaningful changes in global quality of life or symptom scales. Non-hematologic adverse events were mostly grade 1/2; the most frequently reported adverse events in each group were abdominal pain, fatigue, peripheral edema and diarrhea. These data suggest that non-Janus kinase inhibitor therapies provide little improvement in splenomegaly, symptoms or quality of life as compared with placebo. Both COMFORT-I (NCT00952289) and COMFORT-II (NCT00934544) studies have been appropriately registered with clinicaltrials.gov. © 2013 Ferrata Storti Foundation.

    Original languageEnglish
    Pages (from-to)292 - 298
    Number of pages7
    JournalHaematologica
    Volume99
    Issue number2
    DOIs
    Publication statusPublished - 1 Feb 2014

    Cite this